Finished Dosage Form (FDF) export of Sovateltide obtained from Indian Custom Trade Statistics

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Spi-1620, Deeavyfahldiiw, C86h117n17o27, Suc[glu9,ala11,15]et-110-21, (asp-1 = suc-asp), Spi 1620
Molecular Formula
C86H117N17O27
Molecular Weight
1820.9  g/mol
InChI Key
DXPHNGAMYPPTBJ-TZMIJSMNSA-N

Sovateltide
Sovateltide is a highly selective peptide agonist of the endothelin-B receptor. Sovateltide binds to endothelin-B receptors on endothelial cells in tumor blood vessels, which, unlike the angioarchitecture of normal blood vessels, are relatively devoid of smooth muscle. This agent may induce a transient, selective increase in blood flow to a tumor, which may result in an increase in the delivery of anticancer agents to the tumor and, so, an increase in anticancer agent efficacy.
1 2D Structure

Sovateltide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(4S)-4-[[(2S)-4-carboxy-2-[[(2S)-3-carboxy-2-(3-carboxypropanoylamino)propanoyl]amino]butanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
2.1.2 InChI
InChI=1S/C86H117N17O27/c1-11-44(7)71(84(127)100-63(86(129)130)35-50-39-88-54-21-17-16-20-53(50)54)103-85(128)72(45(8)12-2)102-82(125)62(38-69(114)115)98-78(121)57(32-42(3)4)96-80(123)60(36-51-40-87-41-89-51)95-73(116)46(9)91-77(120)58(33-48-18-14-13-15-19-48)97-79(122)59(34-49-22-24-52(104)25-23-49)99-83(126)70(43(5)6)101-74(117)47(10)90-75(118)55(26-29-65(106)107)93-76(119)56(27-30-66(108)109)94-81(124)61(37-68(112)113)92-64(105)28-31-67(110)111/h13-25,39-47,55-63,70-72,88,104H,11-12,26-38H2,1-10H3,(H,87,89)(H,90,118)(H,91,120)(H,92,105)(H,93,119)(H,94,124)(H,95,116)(H,96,123)(H,97,122)(H,98,121)(H,99,126)(H,100,127)(H,101,117)(H,102,125)(H,103,128)(H,106,107)(H,108,109)(H,110,111)(H,112,113)(H,114,115)(H,129,130)/t44-,45-,46-,47-,55-,56-,57-,58-,59-,60-,61-,62-,63-,70-,71-,72-/m0/s1
2.1.3 InChI Key
DXPHNGAMYPPTBJ-TZMIJSMNSA-N
2.1.4 Canonical SMILES
CCC(C)C(C(=O)NC(C(C)CC)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC3=CNC=N3)NC(=O)C(C)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)CCC(=O)O
2.1.5 Isomeric SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Endothelin-1 (8-21), Succinyl-(glu(9),ala(11,15))-

2. Irl 1620

3. Irl-1620

4. Spi-1620

5. Succinyl-(glu(9),ala(11,15))-endothelin-1 (8-21)

6. Succinyl-(glutamyl(9)-alanyl(11,15))-endothelin-1 (8-21)

2.2.2 Depositor-Supplied Synonyms

1. Spi-1620

2. Deeavyfahldiiw

3. C86h117n17o27

4. Suc[glu9,ala11,15]et-110-21

5. (asp-1 = Suc-asp)

6. Spi 1620

7. Gtpl3886

8. Chembl3188091

9. Irl1620

10. Irl2620

11. Mfcd00214284

12. Akos024456459

13. Suc-asp-glu-glu-ala-val-tyr-phe-ala-his-leu-asp-ile-ile-trp-oh

14. Succinyl-(glu9,ala11 Inverted Exclamation Mark Currency15)-endothelin-1 (8-21)

15. Succinyl-(glu9,ala11?15)-endothelin-1 (8-21) (suc-asp-glu-glu-ala-val-tyr-phe-ala-his-leu-asp-ile-ile-trp)

2.3 Create Date
2007-07-04
3 Chemical and Physical Properties
Molecular Weight 1820.9 g/mol
Molecular Formula C86H117N17O27
XLogP32.1
Hydrogen Bond Donor Count23
Hydrogen Bond Acceptor Count28
Rotatable Bond Count56
Exact Mass1819.83048152 g/mol
Monoisotopic Mass1819.83048152 g/mol
Topological Polar Surface Area696 Ų
Heavy Atom Count130
Formal Charge0
Complexity3920
Isotope Atom Count0
Defined Atom Stereocenter Count16
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Drugs in Development

read-more
read-more

Details:

Tycamzzi (Sovateltide), is a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, which is investigated for the treatment of acute cerebral ischemic stroke patients.


Lead Product(s): Sovateltide

Therapeutic Area: Neurology Brand Name: Tycamzzi

Study Phase: ApprovedProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 02, 2023

blank

01

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Details : Tycamzzi (Sovateltide), is a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, which is investigated for the treatment of acute cerebral ischemic stroke patients.

Brand Name : Tycamzzi

Molecule Type : Peptide

Upfront Cash : Not Applicable

October 02, 2023

blank

Details:

Underf the agreement, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi, a selective endothelin B receptor agonist and a new first-in-class drug recently approved for treating cerebral ischemic stroke.


Lead Product(s): Sovateltide

Therapeutic Area: Neurology Brand Name: Tyvalzi

Study Phase: ApprovedProduct Type: Peptide

Sponsor: Sun Pharmaceutical Industries Limited

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement September 13, 2023

blank

02

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Details : Underf the agreement, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi, a selective endothelin B receptor agonist and a new first-in-class drug recently approved for treating cerebral ischemic stroke.

Brand Name : Tyvalzi

Molecule Type : Peptide

Upfront Cash : Undisclosed

September 13, 2023

blank

Details:

Tycamzzi, a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, receives marketing approval in India for the treatment of acute cerebral ischemic stroke. Sovateltide is in Phase 3 trial in US for the same indication.


Lead Product(s): Sovateltide

Therapeutic Area: Neurology Brand Name: Tycamzzi

Study Phase: ApprovedProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 31, 2023

blank

03

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Details : Tycamzzi, a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, receives marketing approval in India for the treatment of acute cerebral ischemic stroke. Sovateltide is in Phase 3 trial in US for the sa...

Brand Name : Tycamzzi

Molecule Type : Peptide

Upfront Cash : Not Applicable

May 31, 2023

blank

Details:

Tycamzzi (sovateltide) is a highly selective endothelin-B receptor agonist, having the potential to be a neuronal progenitor cell therapeutics with anti-apoptotic activity that improves cerebral blood flow and neurological outcome in acute cerebral ischemic stroke patients.


Lead Product(s): Sovateltide

Therapeutic Area: Neurology Brand Name: Tycamzzi

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 13, 2023

blank

04

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Details : Tycamzzi (sovateltide) is a highly selective endothelin-B receptor agonist, having the potential to be a neuronal progenitor cell therapeutics with anti-apoptotic activity that improves cerebral blood flow and neurological outcome in acute cerebral ische...

Brand Name : Tycamzzi

Molecule Type : Peptide

Upfront Cash : Not Applicable

February 13, 2023

blank

Details:

Results of this trial shows highly encouraged regarding the potential of Tycamzzi (sovateltide) to be the first therapeutic since tPA to demonstrate a positive impact on patients suffering from acute ischemic stroke.


Lead Product(s): Sovateltide

Therapeutic Area: Neurology Brand Name: Tycamzzi

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2023

blank

05

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Details : Results of this trial shows highly encouraged regarding the potential of Tycamzzi (sovateltide) to be the first therapeutic since tPA to demonstrate a positive impact on patients suffering from acute ischemic stroke.

Brand Name : Tycamzzi

Molecule Type : Peptide

Upfront Cash : Not Applicable

February 10, 2023

blank

Details:

PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.


Lead Product(s): Sovateltide

Therapeutic Area: Neurology Brand Name: PMZ-1620

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 31, 2022

blank

06

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Details : PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke pa...

Brand Name : PMZ-1620

Molecule Type : Peptide

Upfront Cash : Not Applicable

October 31, 2022

blank

Details:

Tycamzzi (sovateltide), an endothelin-B receptor agonist, has been previously shown to increase cerebral blood flow, have anti-apoptotic activity and produce neurovascular remodeling when administered IV following acute cerebral ischemic stroke in rats.


Lead Product(s): Sovateltide

Therapeutic Area: Neurology Brand Name: Tycamzzi

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 26, 2022

blank

07

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Details : Tycamzzi (sovateltide), an endothelin-B receptor agonist, has been previously shown to increase cerebral blood flow, have anti-apoptotic activity and produce neurovascular remodeling when administered IV following acute cerebral ischemic stroke in rats.

Brand Name : Tycamzzi

Molecule Type : Peptide

Upfront Cash : Not Applicable

October 26, 2022

blank

Details:

PMZ-1620 (sovateltide) is endothelin-B receptor agonist that increases blood flow, shows anti-apoptotic activity, protects neural mitochondria, and produces neurovascular remodeling. Sovateltide is undergoing MA review by CDSCO for acute cerebral ischemic stroke.


Lead Product(s): Sovateltide

Therapeutic Area: Neurology Brand Name: PMZ-1620

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 29, 2022

blank

08

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Details : PMZ-1620 (sovateltide) is endothelin-B receptor agonist that increases blood flow, shows anti-apoptotic activity, protects neural mitochondria, and produces neurovascular remodeling. Sovateltide is undergoing MA review by CDSCO for acute cerebral ischemi...

Brand Name : PMZ-1620

Molecule Type : Peptide

Upfront Cash : Not Applicable

August 29, 2022

blank

Details:

PMZ-1620 having Sovateltide as API, is the Company’s endothelin-B receptor agonist that is also in a Phase III trial for the treatment of cerebral ischemic stroke. In clinical trials, subjects will receive either three intravenous doses of sovateltide, 0.3 ug/kg or a placebo.


Lead Product(s): Sovateltide

Therapeutic Area: Neurology Brand Name: PMZ-1620

Study Phase: IND EnablingProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 03, 2022

blank

09

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Details : PMZ-1620 having Sovateltide as API, is the Company’s endothelin-B receptor agonist that is also in a Phase III trial for the treatment of cerebral ischemic stroke. In clinical trials, subjects will receive either three intravenous doses of sovateltide,...

Brand Name : PMZ-1620

Molecule Type : Peptide

Upfront Cash : Not Applicable

February 03, 2022

blank

Details:

The interim analysis of data indicates a numerical difference indicative of a potential beneficial effect of sovateltide in Alzheimer's disease patients with late early to moderate stage disease.


Lead Product(s): Sovateltide

Therapeutic Area: Neurology Brand Name: PMZ-1620

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 10, 2021

blank

10

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Pharmazz

U.S.A
arrow
ASC 2024
Not Confirmed

Details : The interim analysis of data indicates a numerical difference indicative of a potential beneficial effect of sovateltide in Alzheimer's disease patients with late early to moderate stage disease.

Brand Name : PMZ-1620

Molecule Type : Peptide

Upfront Cash : Not Applicable

June 10, 2021

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/08/21/2933391/0/en/Pharmazz-Inc-and-Sun-Pharma-entered-into-an-agreement-under-which-Sun-Pharma-will-invest-up-to-15-Million-in-Pharmazz-Inc.html

GLOBENEWSWIRE
21 Aug 2024

https://www.globenewswire.com//news-release/2023/10/02/2752648/0/en/A-Special-Protocol-Assessment-Agreement-Reached-with-the-U-S-Food-and-Drug-Administration-for-Phase-3-clinical-trial-of-Sovateltide-for-the-treatment-of-acute-cerebral-ischemic-str.html

GLOBENEWSWIRE
02 Oct 2023

https://www.prnewswire.com/news-releases/pharmazz-inc-announces-us-fda-clearance-for-a-phase-iii-clinical-trial-of-sovateltide-pmz-1620-in-acute-cerebral-ischemic-stroke-patients-301744465.html

PR NEWSWIRE
13 Feb 2023

https://www.prnewswire.com/news-releases/clinical-phase-iii-trial-results-demonstrating-sovateltides-efficacy-to-treat-acute-cerebral-ischemic-stroke-presented-at-the-international-stroke-conference-2023-301741886.html

PR NEWSWIRE
10 Feb 2023

https://www.globenewswire.com/news-release/2022/10/31/2544513/0/en/Pharmazz-Inc-Presents-Positive-Results-of-Phase-III-Clinical-Trial-Demonstrating-Sovateltide-s-Efficacy-as-a-Treatment-for-Acute-Cerebral-Ischemic-Stroke.html

GLOBENEWSWIRE
31 Oct 2022

https://www.globenewswire.com/news-release/2022/08/29/2505915/0/en/Pharmazz-Inc-announces-Indian-Central-Drugs-Standard-Control-Organization-CDSCO-Clearance-of-IND-to-conduct-a-Phase-II-clinical-trial-of-sovateltide-PMZ-1620-in-hypoxic-ischemic-en.html

GLOBENEWSWIRE
29 Aug 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty